Has Laurianne El Musa Penna received payments from drug or device companies?

Yes. Drug and device makers reported $7,191 in general payments to Laurianne El Musa Penna across 228 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Laurianne El Musa Penna did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Laurianne El Musa Penna come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Laurianne El Musa Penna

Endocrinology, Diabetes & Metabolism · Ponce, PRNPI 1629561527

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.9% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations.

$7,191in general payments, 2019–2025

Across 228 payments — averaging $31.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$950
Sanofi-aventis U.S. LLC$690
Boehringer Ingelheim$669
Novo Nordisk$616
Dexcom, Inc.$540
Amgen$446
plus $3K from 18 others

What the payments were for

Travel & lodging$6379%
Food & beverage$6,53491%
Gifts$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	11	$950
Sanofi-aventis U.S. LLC	19	$690
Boehringer Ingelheim	19	$669
Novo Nordisk	28	$616
Dexcom, Inc.	17	$540
Amgen	9	$446
Lilly USA, LLC	4	$439
AstraZeneca	18	$419
PBG Puerto Rico LLC	20	$399
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	28	$343
Eli Lilly Export S.A. Puerto Rico Branch	11	$258
Abbott	8	$158
Novartis	7	$140
AbbVie	6	$127
Kyowa Kirin, Inc.	1	$126
Corcept Therapeutics	2	$125
Rhythm Pharmaceuticals, Inc.	3	$125
Madrigal Pharmaceuticals	1	$118
Perspectum Diagnostics Ltd	1	$117
Bayer	2	$116
Bayer Puerto Rico Inc.	6	$112
Johnson & Johnson	4	$103
Chiesi USA, Inc.	2	$34
Merck	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,191 in reported general payments places this provider in the 65th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres	11	$49,555
TrulicityDulaglutide	19	$19,616
SynthroidLevothyroxine Sodium	67	$3,024
HumalogInsulin Lispro	29	$2,988
LantusInsulin Glargine,hum.Rec.Anlog	28	$1,869
Hydrocortisone	13	$525
Rosuvastatin Calcium	21	$158
Atorvastatin Calcium	24	$145
Alendronate Sodium	11	$100
Metformin Hcl	19	$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
NovartisSandostatin Lar Depot	$140	$49,55511 claims
Lilly USA, LLCTrulicity, Humalog	$439	$22,60448 claims
AbbVieSynthroid	$127	$3,02467 claims
Sanofi-aventis U.S. LLCLantus	$690	$1,86928 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Ponce

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →